Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation

IJC Metabolic and Endocrine

Volumn 6, Issue , 2015, Pages 43-54

  Kolliker Frers R A ^a,b   Bisoendial, R J ^c   Montoya, S F ^b   Kerzkerg, E ^b   Castilla, R ^a   Tak, P P ^c   Milei, J ^a   Capani, F ^a,d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d University John F Kennedy   (Argentina)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Immune system; Inflammation; Psoriatic arthritis

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR3; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HUMAN; HYPERTENSION; IMMUNITY; INFLAMMATION; INFORMATION PROCESSING; METABOLIC REGULATION; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS;

EID: 84961288802     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2015.01.005     Document Type: Review

References (161)

1. Anichkov N., Chalatov S. Ueber experimentelle Cholesterinsteatose: Ihre Bedeutung fur die Enstehung einiger pathologischer Prozessen. Centrbl Allg Pathol Pathol Anat 1913, 24:1-9.
2. Hansson G.K. Atherosclerosis-an immune disease: the Anitschkov Lecture 2007. Atherosclerosis 2009, 202(1):2-10.
3. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
4. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013 Feb, 133(2):377-385.
5. Nickoloff B.J., Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004, 113(12):1664-1675.
6. Gladman D.D. Psoriatic arthritis. Dermatol Ther 2009, 22(1):40-55.
7. Bisoendial R.J., Stroes E.S., Tak P.P. Where the immune response meets the vessel Wall. Neth J Med 2009, 67(8):328-333.
8. Gladman D.D., Farewell V.T., Wong K., Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998, 41(6):1103-1110.
9. Nickoloff B.J. The cytokine network in psoriasis. Arch Dermatol 1991, 127(6):871-884.
10. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007, 156(2):271-276.
11. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296(14):1735-1741.
12. Racz E., Prens E.P. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med 2009, 11:e38.
13. Vollmer S., Menssen A., Prinz J.C. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 2001, 117(5):1296-1301.
14. Ross E.L., D'Cruz D., Morrow W.J. Localized monocyte chemotactic protein-1 production correlates with T cell infiltration of synovium in patients with psoriatic arthritis. J Rheumatol 2000, 27(10):2432-2443.
15. Deleuran M., Buhl L., Ellingsen T., Harada A., Larsen C.G., Matsushima K., et al. Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. J Dermatol Sci 1996, 13(3):228-236.
16. Milei J., Parodi J.C., Alonso G.F., Barone A., Grana D., Matturri L. Carotid rupture and intraplaque hemorrhage: immunophenotype and role of cells involved. Am Heart J 1998, 136(6):1096-1105.
17. Nilsson J., Wigren M., Shah P.K. Vaccines against atherosclerosis. Expert Rev Vaccines 2013, 12(3):311-321.
18. Klingenberg R., Gerdes N., Badeau R.M., Gistera A., Strodthoff D., Ketelhuth D.F., et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 2013, 123(3):1323-1334.
19. Beinsberger J., Heemskerk J.W., Cosemans J.M. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum Jun 26 2014, [Pii: S0049-0172(14)00162-0. [Epub ahead of print] Review]. 10.1016/j.semarthrit.2014.06.006.
20. Scarno A., Perrotta F.M., Cardini F., Carboni A., Annibali G., Lubrano E., et al. Beyond the joint: subclinical atherosclerosis in rheumatoid arthritis. World J Orthop Jul 18 2014, 5(3):328-335. [ECollection 2014 Jul 18. Review]. 10.5312/wjo.v5.i3.328.
21. García-Gómez C., Bianchi M., de la Fuente D., Badimon L., Padró T., Corbella E., et al. Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: a qualitative relationship?. World J Orthop Jul 18 2014, 5(3):304-311. [ECollection 2014 Jul 18. Review]. 10.5312/wjo.v5.i3.304.
22. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
23. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl. 2):ii14-7.
24. Angel K., Provan S.A., Gulseth H.L., Mowinckel P., Kvien T.K., Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010, 55(2):333-338.
25. Ogdie A1., Haynes K., Troxel A.B., Love T.J., Hennessy S., Choi H., et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis 2014, 73(1):149-153.
26. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55(5):829-835.
27. Eder L., Jayakar J., Shanmugarajah S., Thavaneswaran A., Pereira D., Chandran V., et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis 2013, 72(5):715-720.
28. Brauchli Y.B., Jick S.S., Miret M., Meier C.R. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009, 160(5):1048-1056.
29. Prodanovich S., Kirsner R.S., Kravetz J.D., Ma F., Martinez L., Federman D.G. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009, 145(6):700-703.
30. Ritchlin C. Psoriatic disease-from skin to bone. Nat Clin Pract Rheumatol 2007, 3(12):698-706.
31. Pryshchep O., Ma-Krupa W., Younge B.R., Goronzy J.J., Weyand C.M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008, 118(12):1276-1284.
32. Sattar N., Crompton P., Cherry L., Kane D., Lowe G., McInnes I.B. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007, 56(3):831-839.
33. Alexandroff A.B., Pauriah M., Camp R.D., Lang C.C., Struthers A.D., Armstrong D.J. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161(1):1-7.
34. Kashiwagi M., Imanishi T., Ozaki Y., Satogami K., Masuno T., Wada T., et al. Differential expression of Toll-like receptor 4 and human monocyte subsets in acute myocardial infarction. Atherosclerosis 2012, 221(1):249-253.
35. Palikhe A., Sinisalo J., Seppanen M., Haario H., Meri S., Valtonen V., et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007, 99(7):890-895.
36. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370(9583):263-271.
37. Kumar N., Armstrong D.J. Cardiovascular disease-the silent killer in rheumatoid arthritis. Clin Med 2008, 8(4):384-387.
38. Alexandroff A.B., Pauriah M., Camp R.D., Lang C.C., Struthers A.D., Armstrong D.J. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161(1):1-7.
39. Szodoray P., Alex P., Chappell-Woodward C.M., Madland T.M., Knowlton N., Dozmorov I., et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007, 46(3):417-425.
40. Ballara S., Taylor P.C., Reusch P., Marme D., Feldmann M., Maini R.N., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44(9):2055-2064.
41. Winterfield L.S., Menter A., Gordon K., Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005, 64(Suppl. 2):ii87-90. [discussion ii1-2].
42. Chandran V., Bull S.B., Pellett F.J., Ayearst R., Pollock R.A., Gladman D.D. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology 2014, 53(2):233-239.
43. Rose S., Stansky E., Dagur P.K., Samsel L., Weiner E., Jahanshad A., et al. Characterization of immune cells in psoriatic adipose tissue. J Transl Med 2014, 12(1):258. [16].
44. Lintermans L.L., Stegeman C.A., Heeringa P., Abdulahad W.H. T cells in vascular inflammatory diseases. Front Immunol 2014, 14(5):504.
45. van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005, 437(7060):906-910.
46. Tupin E., Nicoletti A., Elhage R., Rudling M., Ljunggren H.G., Hansson G.K., et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004, 199(3):417-422.
47. Armstrong A.W., Voyles S.V., Armstrong E.J., Fuller E.N., Rutledge J.C. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011, 63(1):1-9.
48. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
49. Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006, 47(8 Suppl.):C19-C31.
50. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107(3):499-511.
51. Fon Tacer K., Kuzman D., Seliskar M., Pompon D., Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes. Physiol Genomics 2007, 31(2):216-227.
52. Raychaudhuri S.P. Comorbidities of psoriatic arthritis 440 metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012, 39(2):437-440.
53. Danning C.L., Illei G.G., Hitchon C., Greer M.R., Boumpas D.T., McInnes I.B. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000, 43(6):1244-1256.
54. Mestas J., Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008, 18(6):228-232.
55. Fenyo I.M., Gafencu A.V. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 2013, 218(11):1376-1384.
56. Zhang H., Park Y., Wu J., Chen X., Lee S., Yang J., et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009, 116(3):219-230.
57. Uyemura K., Demer L.L., Castle S.C., Jullien D., Berliner J.A., Gately M.K., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996, 97(9):2130-2138.
58. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009, 102(2):215-222.
59. Kibler J.L., Tursich M., Ma M., Malcolm L., Greenbarg R. Metabolic, autonomic and immune markers for cardiovascular disease in posttraumatic stress disorder. World J Cardiol 2014, 6(6):455-461. [26].
60. Ingegnoli F., Fantini F., Favalli E.G., Soldi A., Griffini S., Galbiati V., et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008, 31(2):175-179.
61. Matsuzawa Y. Adipocytokines and metabolic syndrome. Semin Vasc Med 2005, 5(1):34-39.
62. Yin Y.W., Hu A.M., Sun Q.Q., Liu H.L., Wang Q., Zeng Y.H., et al. Association between interleukin-6 gene -174G/C polymorphism and the risk of coronary heart disease: a meta-analysis of 20 studies including 9619 cases and 10,919 controls. Gene 2012, 503(1):25-30.
63. Rauramaa R., Vaisanen S.B., Luong L.A., Schmidt-Trucksass A., Penttila I.M., Bouchard C., et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20(12):2657-2662.
64. Rundek T., Elkind M.S., Pittman J., Boden-Albala B., Martin S., Humphries S.E., et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002, 33(5):1420-1423.
65. Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012, 379(9822):1214-1224.
66. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86(2):515-581.
67. Sikorski K., Czerwoniec A., Bujnicki J.M., Wesoly J., Bluyssen H.A. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 2011, 22(4):211-219.
68. Lee D.M., Friend D.S., Gurish M.F., Benoist C., Mathis D., Brenner M.B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297(5587):1689-1692.
69. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009, 183(5):3170-3176.
70. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011, 121(9):3375-3383.
71. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24(2):179-189.
72. Hamed S.A., Hamed E.A., Ezz Eldin A.M., Mahmoud N.M. Vascular risk factors, endothelial function, and carotid thickness in patients with migraine: relationship to atherosclerosis. J Stroke Cerebrovasc Dis 2010, 19(2):92-103.
73. Bonifati C., Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999, 38(4):241-251.
74. Maurer M., Wedemeyer J., Metz M., Piliponsky A.M., Weller K., Chatterjea D., et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004, 432(7016):512-516.
75. Ridker P.M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004, 109(16):1955-1959.
76. Wick G., Knoflach M., Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004, 22:361-403.
77. Jialal I., Devaraj S., Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 2004, 44(1):6-11.
78. Bisoendial R., Birjmohun R., Keller T., van Leuven S., Levels H., Levi M., et al. In vivo effects of C-reactive protein (CRP)-infusion into humans. Circ Res 2005, 97(12):e115-e116.
79. Qamirani E., Ren Y., Kuo L., Hein T.W. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD (P) H oxidase. Arterioscler Thromb Vasc Biol 2005, 25(5):995-1001.
80. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106(12):1439-1441.
81. Strober B., Teller C., Yamauchi P., Miller J.L., Hooper M., Yang Y.C., et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008, 159(2):322-330.
82. Kaur S., Zilmer K., Leping V., Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol 2011, 25(11):1328-1333.
83. Cowan K.N., Jones P.L., Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000, 105(1):21-34.
84. Shi Y., Patel S., Niculescu R., Chung W., Desrochers P., Zalewski A. Role of matrix metalloproteinases and their tissue inhibitors in the regulation of coronary cell migration. Arterioscler Thromb Vasc Biol 1999, 19(5):1150-1155.
85. Chandran V., Gladman D.D. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010, 12(4):288-294.
86. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278(3):1910-1914.
87. Kirkham B.W., Kavanaugh A., Reich K. IL-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis, and rheumatoid arthritis. Immunology 2014 Feb, 141(2):133-142. 10.1111/imm.12142.
88. Madhur M.S., Funt S.A., Li L., Vinh A., Chen W., Lob H.E., et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31(7):1565-1572.
89. Hashmi S., Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006, 17(8):699-706.
90. Chabaud M., Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44(6):1293-1303.
91. Jhun J.Y., Yoon B.Y., Park M.K., Oh H.J., Byun J.K., Lee S.Y., et al. Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation. Exp Mol Med 2012 Jul 31, 44(7):424-431. 10.3858/emm.2012.44.7.047.
92. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130(5):1373-1383.
93. George J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2008, 5(9):531-540.
94. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133(5):775-787.
95. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9(3):239-244.
96. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127(1):89-97.
97. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2(8):e779.
98. Chen L., Shen Z., Wang G., Fan P., Liu Y. Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris. J Dermatol Sci 2008, 51(3):200-203.
99. Armstrong A.W., Voyles S.V., Armstrong E.J., Fuller E.N., Rutledge J.C. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011, 20(7):544-549.
100. Kagen M.H., McCormick T.S., Cooper K.D. Regulatory T cells in psoriasis. Ernst Schering Res Found Workshop 2006, 56:193-209.
101. Flisiak I., Chodynicka B., Porebski P., Flisiak R. Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 2002, 19(3):121-125.
102. Flisiak I., Zaniewski P., Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity. Biomarkers 2008, 13(5):549-556.
103. Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85(8):e17-e24.
104. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89(10):930-934.
105. Tuluc F., Lai J.P., Kilpatrick L.E., Evans D.L., Douglas S.D. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009, 30(6):271-276.
106. Cohen A.D., Weitzman D., Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010, 90(1):23-26.
107. Driessen R.J., Boezeman J.B., Van De Kerkhof P.C., De Jong E.M. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 2009, 20(1):42-47.
108. Wu Y., Mills D., Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008, 7(4):373-377.
109. Dalbeth N., Pool B., Smith T., Callon K.E., Lobo M., Taylor W.J., et al. Circulating mediators of bone remodelling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010, 12(4):R164.
110. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007, 56(4):629-634.
111. Brauchli Y.B., Jick S.S., Meier C.R. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008, 159(6):1331-1337.
112. Marra M., Campanati A., Testa R., Sirolla C., Bonfigli A.R., Franceschi C., et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007, 20(4):731-736.
113. Wu J.J., Tsai T.F. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol 2008, 144(10):1403-1404.
114. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007, 167(15):1670-1675.
115. Gisondi P., Cotena C., Tessari G., Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008, 22(3):341-344.
116. Li W., Han J., Choi H.K., Qureshi A.A. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012, 175(5):402-413.
117. Fortes C., Mastroeni S., Leffondre K., Sampogna F., Melchi F., Mazzotti E., et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005, 141(12):1580-1584.
118. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005, 125(1):61-67.
119. Armstrong A.W., Armstrong E.J., Fuller E.N., Sockolov M.E., Voyles S.V. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011, 165(6):1162-1168.
120. Kimball A.B., Gladman D., Gelfand J.M., Gordon K., Horn E.J., Korman N.J., et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008, 58(6):1031-1042.
121. Dreiher J., Weitzman D., Davidovici B., Shapiro J., Cohen A.D. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008, 88(6):561-565.
122. Cohen A.D., Sherf M., Vidavsky L., Vardy D.A., Shapiro J., Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008, 216(2):152-155.
123. Cohen A.D., Gilutz H., Henkin Y., Zahger D., Shapiro J., Bonneh D.Y., et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007, 87(6):506-509.
124. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007, 157(1):68-73.
125. Tam L.S., Shang Q., Li E.K., Tomlinson B., Chu T.T., Li M., et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008, 59(9):1322-1331.
126. Han C., Robinson D.W., Hackett M.V., Paramore L.C., Fraeman K.H., Bala M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33(11):2167-2172.
127. Kimhi O., Caspi D., Bornstein N.M., Maharshak N., Gur A., Arbel Y., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36(4):203-209.
128. Tam L.S., Tomlinson B., Chu T.T., Li M., Leung Y.Y., Kwok L.W., et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 2008, 47(5):718-723.
129. Gladman D.D., Ang M., Su L., Tom B.D., Schentag C.T., Farewell V.T. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68(7):1131-1135.
130. Cassano N., Carbonara M., Panaro M., Vestita M., Vena G.A. Role of serum uric acid in conditioning the association of psoriasis with metabolic syndrome. Eur J Dermatol 2011, 21(5):808-809.
131. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Gomez-Acebo I., Miranda-Filloy J.A., Paz-Carreira J., et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009, 39(3):157-162.
132. Takahashi H., Tsuji H., Hashimoto Y., Ishida-Yamamoto A., Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010, 35(6):645-649.
133. Nofal A., Al-Makhzangy I., Attwa E., Nassar A., Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 2009, 23(7):803-806.
134. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001, 7(4):425-429.
135. Stannard A.K., Khurana R., Evans I.M., Sofra V., Holmes D.I., Zachary I. Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 2007, 27(3):494-502.
136. Kuehl F.A., Egan R.W. Prostaglandins, arachidonic acid, and inflammation. Science 1980, 210(4473):978-984.
137. Kuhn H., Thiele B.J. The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. FEBS Lett 1999, 449(1):7-11.
138. Babior B.M. NADPH oxidase: an update. Blood 1999, 93(5):1464-1476.
139. Hampton M.B., Kettle A.J., Winterbourn C.C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998, 92(9):3007-3017.
140. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108(16):1912-1916.
141. Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006, 55(4):531-536.
142. Skaaby T., Husemoen L.L., Martinussen T., Thyssen J.P., Melgaard M., Thuesen B.H., et al. Vitamin D status, filaggrin genotype, and cardiovascular risk factors: a Mendelian randomization approach. PLoS One 2013, 8(2):e57647.
143. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92(9):3893-3897.
144. Deleskog A., Piksasova O., Silveira A., Samnegard A., Tornvall P., Eriksson P., et al. Serum 25-hydroxyvitamin D concentration, established and emerging cardiovascular risk factors and risk of myocardial infarction before the age of 60years. Atherosclerosis 2012, 223(1):223-229.
145. Mahon B.D., Wittke A., Weaver V., Cantorna M.T. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003, 89(5):922-932.
146. Hewison M. Vitamin D, and innate and adaptive immunity. Vitam Horm 2011, 86:23-62.
147. Hegyi Z., Zwicker S., Bureik D., Peric M., Koglin S., Batycka-Baran A., et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol 2012, 132(5):1416-1424.
148. van der Aar A.M., Sibiryak D.S., Bakdash G., van Capel T.M., van der Kleij H.P., Opstelten D.J., et al. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol 2011, 127(6):1532-1540. [e7].
149. Icen M., Nicola P.J., Maradit-Kremers H., Crowson C.S., Therneau T.M., Matteson E.L., et al. Systemic lupus erythematosus features in rheumatoid arthritis and their effect on overall mortality. J Rheumatol 2009, 36(1):50-57.
150. Listing J., Strangfeld A., Kekow J., Schneider M., Kapelle A., Wassenberg S., et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58(3):667-677.
151. Avouac J., Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008, 9(7):1121-1128.
152. Pereira I.A., Borba E.F. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 2008, 138(37-38):534-539.
153. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92(9):3893-3897.
154. Harris G.D., White R.D. Lifestyle modifications for the prevention and treatment of cardiovascular disease: an evidence-based approach. Mo Med 2004, 101(3):222-226.
155. Grignani G., Maiolo A. Cytokines and hemostasis. Haematologica 2000, 85(9):967-972.
156. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117(2):244-279.
157. Speiser W., Kapiotis S., Kopp C.W., Simonitsch I., Jilma B., Jansen B., et al. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 2001, 85(2):362-367.
158. Patel J.N., Jager A., Schalkwijk C., Corder R., Douthwaite J.A., Yudkin J.S., et al. Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci (Lond) 2002, 103(4):409-415.
159. Montaudie H., Albert-Sabonnadiere C., Acquacalda E., Fontas E., Danre A., Roux C., et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2012 Jul 31, 44(7):424-431. 10.3858/emm.2012.44.7.047.
160. Andreakos E., Foxwell B., Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol Rev 2004, 202:250-265.
161. Vimaleswaran K.S., Berry D.J., Lu C., Tikkanen E., Pilz S., Hiraki L.T., et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med 2013, 10(2):e1001383.